Hims & Hers screens below the minimum quality threshold, trades above its resistance-based price target with negative expected return from current levels, and carries 33% short interest in a confirmed downtrend; the risk/reward geometry is unfavorable, with downside exceeding upside, and the balance of evidence supports reducing rather than building the position.
Thesis pillars
- Quality Below Minimum No Moat→Stable
- Extreme Short Interest Downside Signal↓Deteriorating
- Price Above Target Negative Geometry↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 23, 2026· older than 90 days
Hims & Hers Health, Inc. (HIMS) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Engine safety override at $25.70: Risk below floor (2.1 < 2.5) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: High short interest: 28%; Below-average business quality; Negative price momentum.
Hims & Hers Health operates a telehealth platform for prescription and OTC products across sexual health, hair loss, weight loss, dermatology, and mental health in the US, UK, Canada, and EU. Revenue grew from $872 million in 2023 to $2.35 billion in 2025, primarily from US... Read more
Sell if holding. Engine safety override at $25.70: Risk below floor (2.1 < 2.5) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: High short interest: 28%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.1/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 5d<=7d. Suitability: speculative.
About Hims & Hers Health, Inc.
About Hims & Hers Health, Inc.
Hims & Hers Health grew revenues from $872 million in 2023 to $1.5 billion in 2024 to $2.35 billion in 2025, with a substantial majority derived from subscription-based prescription product sales in the United States. The company had 2,442 employees at year-end 2025, up from 1,046 at year-end 2023. Since its 2017 launch, the platform has facilitated over fifty million telehealth consultations in the US, Canada, the UK, and the EU.
Hims & Hers earns revenue through subscriptions billed on 30- to 360-day cadences for prescription and OTC products spanning sexual health, hair loss, weight management, hormone health, dermatology, and mental health. Prescriptions are written by providers in Affiliated Medical Groups—separate professional corporations established to navigate state corporate practice of medicine prohibitions—and fulfilled through the company's own licensed 503A pharmacies and a 503B compounding outsourcing facility. The company also operates a peptide manufacturing facility and a laboratory testing services facility. In the UK and EU, the company directly employs physicians through subsidiaries including Zava UK, which operates partnerships with Asda Stores Limited and Superdrug Stores PLC. New customers arrive through social media, television, direct mail, online search, retail store presence, and influencer campaigns.
Show full overview
Regulatory pressure is most concentrated in compounded GLP-1 medications, where the FDA resolved a semaglutide shortage on February 21, 2025—limiting use of 503B outsourcing facilities for compounded semaglutide at scale—before issuing a February 2026 statement naming Hims & Hers directly for intending to restrict GLP-1 active pharmaceutical ingredients for mass-marketed compounded drugs. That same month, the HHS General Counsel referred the company to the Department of Justice for potential violations of the FDCA and applicable Title 18 provisions. The 10-K cautions that any resulting actions may require significant resources, cause reputational harm, or result in operational disruptions that could adversely affect financial condition and cash flows.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Hims & Hers Health, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated Nov 2, 2026Recent Developments — Hims & Hers Health, Inc.
Latest news
- NEWS Lead Plaintiff Deadline for Hims & Hers Securities Class Action Lawsuit — fiscal.ai Nov 2, 2026 negative
- NEWS U.S. Department Of Health And Human Services Announces Availability Of Enforcement Discretion Policy Regarding 503a Comp — benzinga Oct 28, 2026 neutral
- NEWS 10 Health Care Stocks Whale Activity In Today’s Session — benzinga Oct 23, 2026 neutral
- NEWS Hims & Hers misses revenue estimates as strategy shift hits sales - Reuters — Reuters May 11, 2026 negative
- NEWS Hims earnings today: Why Hims & Hers Health stock dropped despite raising revenue forecast - here's what i - The Economi — The Economic Times May 11, 2026 negative
Latest item Nov 2, 2026 · Generated 2026-11-04T11:59:36Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicUnited States10-K Item 1A: 'In the United States, we derive a substantial majority of our revenue from customers' subscription-based purchases of prescription products made available through our platform'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Volatile — 7.3% daily ATR makes tight stops impractical. Position-size conservatively.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $25.70: Risk below floor (2.1 < 2.5) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: High short interest: 28%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $24.39. Score 5.1/10, moderate confidence.
Analyst target: $27.10 (+5.5% upside). Prior stop was $24.39. Stop-loss: $24.39.
Concentration risk — Geographic: United States; Risk below floor (2.1 < 2.5).
Hims & Hers Health, Inc. trades at a P/E of N/A (forward 34.9). TrendMatrix value score: 6.1/10. Verdict: Sell.
22 analysts rate HIMS, with a consensus score of 3.5/5. 13 analysts publish price targets averaging $31.
What does Hims & Hers Health, Inc. do?Hims & Hers Health operates a telehealth platform for prescription and OTC products across sexual health, hair loss,...
Hims & Hers Health operates a telehealth platform for prescription and OTC products across sexual health, hair loss, weight loss, dermatology, and mental health in the US, UK, Canada, and EU. Revenue grew from $872 million in 2023 to $2.35 billion in 2025, primarily from US subscription purchases. The company fulfills most prescriptions through its own licensed pharmacies and a 503B compounding outsourcing facility.